← Non-small cell lung cancer investigators

Giovanni Selvaggi, MD

Xcovery Holdings, Inc. · CEO

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

NIH RePORTER

Trial papers in non-small cell lung cancer

PubMed author-name match

Trials

Studies that name Giovanni Selvaggi, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:19 UTC. Open this list on ClinicalTrials.gov

Ph1
NCT05665283 · A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted Conditions
Xcovery Holdings, Inc. · completed · Bioequivalency · principal investigator
Ph3
NCT02767804 · eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Xcovery Holdings, Inc. · active not recruiting · Non-small Cell Lung Cancer · study chair

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.